BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 10, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 27, 2002
View Archived Issues
Metformin XT is equivalent to immediate-release metformin in the treatment of type 2 diabetes
Read More
Use of LY-333531 in the treatment of diabetic complications
Read More
Eletriptan now available in Germany for migraine Rx
Read More
Nonapprovable letter issued for Casodex in early prostate cancer
Read More
AuraZyme awarded grant for drug delivery system development
Read More
Hydro Med obtains option to biodegradable polymer drug delivery system
Read More
BiDil to be evaluated in African American heart failure population
Read More
Alza and TransForm collaborate on drug optimization
Read More
Ixion receives grant for stem cell research in diabetes
Read More
FDA approves injectable Geodon for schizophrenia
Read More
ImmunoGen faces development setbacks with two TAP products
Read More
AMG-073 provides long-term benefits in primary hyperparathyroidism
Read More
Acyline suppresses testosterone in men for at least 19 days with minimal side effects
Read More
First-in-class SARM with strong anabolic effects characterized at ENDO 2002
Read More
AstraZeneca describes novel N-type calcium channel antagonists
Read More
Neurotrophin activity enhancers reported in Sankyo patent
Read More
Novel CNS-selective prostacyclin receptor ligands and their use
Read More
Comparative effects of SOM-230 and octreotide on GH and prolactin release
Read More
Angiogenesis inhibitors in early development at Sigma-Tau
Read More
New PARP inhibitors in GSK pipeline
Read More
FDA deems Vevesca nonapprovable
Read More
Lilly Icos continues to develop PDE5 inhibitors
Read More
Changes in Pennsaid marketing and distribution agreements
Read More
Radiolabeled CCR1 antagonists for use in diagnosis of AD
Read More
Preclinical and early clinical findings for TAK-013, a potent oral GnRH receptor antagonist
Read More
Nymox files NX-1207 IND in benign prostatic hyperplasia
Read More
ATL-962 cleared to enter phase IIb trial for obesity
Read More
Enrollment completed in phase II trial of tesmilifene combination therapy in prostate cancer
Read More
